Aristotle University Of Thessaloniki (AUTH)
Επίδραση της ενδοφλέβιας χορήγησης βιταμίνης D στην ινσουλινοαντίσταση των χρόνιων αιμοκαθαιρόμενων ασθενών
Abstract
dc:descriptionIt is widely known that in the chronic kidney disease some of the most important complications are the insulin resistance and the endothelium dysfunction. Various factors, such as the secondary hyperparathyroidism, the anemia, the metabolic acidosis and the vitamin D deficiency, involved in these metabolic disorders. According to the existing literature parathyroid hormone suppresses the production of insulin from the b-cells of pancreas, whereas inversely, Vitamin D augments its excretion and improves the use of glucose peripherally. It has not been adequately clarified yet the effect of Vitamin D in the resistance to the insulin as well as to the levels of the nitric oxide and endothelin-1 in the case of patients chronically subjected to dialysis. The aim of the study was to investigate the influence of the intravenous administration of Vitamin D in the insulin resistance and in the levels of nitric oxide and endothelin-1 in the dialysis patients. Patients and Methods: Twenty-six (26) patients on chronic dialysis were included in this study, being 17 of them men and 9 of them women, with an age average of 56.4±13.5 years. These patients were subjected to a 3-week dialysis program for duration of 71.9±66.7 months. All of the patients were suffering from secondary hyperparathyroidism and they had not received treatment with Vitamin D for a period of time greater than thirty (30) days. The patients were divided into two groups; the A group and the B group. In the A group alfacalcidol was given intravenously in a proportion of 1 to 1.5 mcg per dialysis session, whereas in the B group paricalcitol in a proportion of [iPTH]/80 mcg per session. Three blood samples were practiced in total (T0: before the beginning of the Vitamin D administration, T1 and T2: one month and three months after the beginning of Vitamin D administration) and the levels of iPTH, insulin, glucose, ΝΟ, ΕΤ-1, ΗΟΜΑ, Ca, P and CaXP product were measured. The dose of alfacalcidol was not fixed during the study period, while the dose of the paricalcitol was adapted to the levels of iPTH one month after the beginning of the study. In the study were included also 18 healthy persons (seven (7) men and (11) women) with an age average of 48± 11 years, in which were measured the parameters of the study and constituted the group C (control group) without having received Vitamin C. Results: In the beginning of the study, groups A and B had statistically significant difference, concerning group C (control group), in the levels of phosphorous, CaXP product, insulin, HOMA, iPTH, NO and ET-1 (p<0.05), while there was no significant difference in the levels of Ca and glucose. Among the groups A and B there was statistically significant difference only in the level of iPTH, with higher levels in the group B. The levels of iPTH decreased significantly one month after the administration of paricalcitol (in the group B) and were retained until the end of the study, whereas no significant change was found in the amount of iPTH in the group A (administration of alfacalcidol). Significant decrease of Insulin levels and HOMA index values was observed in both groups (A and B), approaching the values concerning group C. The decrease of Insulin levels and HOMA index was irrelevant to the variations of iPTH in group A, while in the group B this decrease was observed parallel to the decrease of iPTH level during the first month, but was retained until the end of the study, even after the reduction of paricalcitol dose and the growing tendency of iPTH. The levels of NO presented a tendency of increase, while those of the ET-1 a tendency of decrease, without however these variations being statistically significant. In conclusions our study showed that 1) the intravenous administration of both types of Vitamin D improves the resistance to the Insulin in the case of patients chronically subjected to dialysis. 2) The administration of alfacalcidol significantly improves the resistance to the Insulin independently of the iPTH variations. 3) The intravenous administration of paricalcitol improved also significantly the resistance to the Insulin, without, nevertheless, being absolutely clear if this improvement was due to the reduction of the iPTH or due to the ‘non classical’ action influence of paricalcitol or finally due to both factors. The improvement of Insulin resistance was retained even with the administration of lesser dose of paricalcitol after the decrease of iPTH, which accentuates further the importance of ‘non classical’ actions influence of the Vitamin D. 4) The improvement of the resistance to the Insulin was not accompanied with significant improvement of the endothelium dysfunction indexes (NO and ET-1), although there was a tendency of increase of NO and tendency of decrease of ET-1, which intimates a possible long lasting improvement.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Liakos, Spyridon
- Λιάκος, Σπυρίδων
Subjects
dc:subject × 20- Ινσουλίνη, Αντίσταση στην
- Βιταμίνη D
- Αλφακαλσιδόλη
- Παρικαλσιτόλη
- Δευτεροπαθής υπερπαραθυρεοειδισμός
- Αιμοκάθαρση
- Μονοξείδιο αζώτου (NO)
- Ενδοθηλίνη-1 (ΕΤ-1)
- Insulin resistance
- Vitamin D
- Alphacalsidol
- Paricalsitol
- Secondary hyperparathyroidism
- Dialysis
- Nitric oxide (NO)
- Endothelin-1
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19548